Half life of lisinopril
Pro Research Analysisby 
Searched over 200M research papers
Understanding the Half-Life of Lisinopril
Introduction to Lisinopril Pharmacokinetics
Lisinopril is a widely used angiotensin-converting enzyme (ACE) inhibitor, primarily prescribed for the treatment of hypertension and congestive heart failure. Its pharmacokinetic properties, including absorption, bioavailability, and elimination, are crucial for understanding its therapeutic efficacy and dosing regimen.
Effective Half-Life of Lisinopril
The effective half-life of lisinopril, which is the time it takes for the drug concentration to reduce by half in the body during chronic administration, averages around 12.6 hours . This half-life is significant because it determines the dosing frequency, ensuring that the drug maintains its therapeutic effect over a 24-hour period with once-daily dosing.
Terminal Serum Half-Life
In contrast to the effective half-life, the terminal serum half-life of lisinopril is approximately 40 hours . This longer half-life is attributed to the drug's binding to ACE, which prolongs its presence in the serum. However, this terminal phase is not predictive of the steady-state parameters, which are more relevant for clinical dosing.
Impact of Renal Function on Half-Life
Renal function significantly affects the half-life of lisinopril. In patients with normal renal function, the elimination half-life remains around 12.6 hours . However, in patients with impaired renal function, the half-life is prolonged due to reduced clearance. For instance, in patients with severe renal impairment, the half-life can be doubled or even tripled, necessitating dosage adjustments to avoid drug accumulation and potential toxicity.
Conclusion
The pharmacokinetics of lisinopril, particularly its effective and terminal half-lives, are essential for optimizing its therapeutic use. The effective half-life of 12.6 hours supports once-daily dosing, while the longer terminal half-life reflects prolonged drug binding to ACE. Renal function plays a critical role in drug clearance, highlighting the need for careful dose management in patients with renal impairment. Understanding these parameters ensures that lisinopril is used safely and effectively in various patient populations.
Sources and full results
Most relevant research papers on this topic